Works matching IS 02780232 AND DT 2022 AND VI 40 AND IP 3
Results: 20
Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myeloma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 417, doi. 10.1002/hon.3016
- By:
- Publication type:
- Article
Targeting MYC and BCL2 by a natural compound for "double‐hit" lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 356, doi. 10.1002/hon.3010
- By:
- Publication type:
- Article
Exome sequencing identifies PD‐L2 as a potential predisposition gene for lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 475, doi. 10.1002/hon.3033
- By:
- Publication type:
- Article
Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 390, doi. 10.1002/hon.3014
- By:
- Publication type:
- Article
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 442, doi. 10.1002/hon.3000
- By:
- Publication type:
- Article
Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 320, doi. 10.1002/hon.3002
- By:
- Publication type:
- Article
Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 400, doi. 10.1002/hon.2996
- By:
- Publication type:
- Article
The superiority of Epstein‐Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV‐positive NK‐cell lymphoproliferative diseases.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 381, doi. 10.1002/hon.2998
- By:
- Publication type:
- Article
A novel clinical immune‐related prognostic model predicts the overall survival of mantle cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 343, doi. 10.1002/hon.2994
- By:
- Publication type:
- Article
Multi‐trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 409, doi. 10.1002/hon.2992
- By:
- Publication type:
- Article
Current perspectives regarding SARS‐CoV‐2 vaccination in chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 313, doi. 10.1002/hon.2990
- By:
- Publication type:
- Article
Racial differences in the survival of mantle cell lymphoma patients in the United States.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 479, doi. 10.1002/hon.2984
- By:
- Publication type:
- Article
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 332, doi. 10.1002/hon.2982
- By:
- Publication type:
- Article
Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 457, doi. 10.1002/hon.2980
- By:
- Publication type:
- Article
The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 370, doi. 10.1002/hon.2978
- By:
- Publication type:
- Article
Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapy.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 482, doi. 10.1002/hon.2976
- By:
- Publication type:
- Article
Prognostic significance of IKZF1 deletions and IKZF1<sup>plus</sup> profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM 2009 protocol.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 430, doi. 10.1002/hon.2973
- By:
- Publication type:
- Article
Promising clinical efficacy and acceptable safety profile of sequential P‐GEMOX and radiotherapy for localized ENKTL.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 341, doi. 10.1002/hon.2970
- By:
- Publication type:
- Article
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 469, doi. 10.1002/hon.2966
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 311, doi. 10.1002/hon.2891
- Publication type:
- Article